Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer … (Abstract)

Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care Cochrane Database Syst Rev 05 June 2018 https://www.ncbi.nlm.nih.gov/pubmed/29869799 Background: Opioid-induced bowel dysfunction (OIBD) is characterised by constipation, incomplete evacuation, bloating, and gastric reflux. It is one of the major adverse events of treatment for pain in cancer and in palliative […]

Severe pruritus of cholestasis in disseminated cancer… (Abstract)

Severe pruritus of cholestasis in disseminated cancer: developing a rational treatment strategy. A case report J Pain Symptom Manage January 2005 https://www.sciencedirect.com/science/article/pii/S0885392404003914 Severe pruritus is a frequent complication of cholestasis. Both serotonin and opioids play an important role in the development of this symptom. Guidelines to provide rational management of pruritus of cholestasis do not […]

Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders (Abstract)

Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders Int J Pharm Compd Mar-Apr 2010 https://mail.google.com/mail/u/0?ui=2&ik=b5d7923c33&attid=0.2&permmsgid=msg-f:1668161843235939361&th=1726805badf06421&view=att&disp=safe Use of low dose naltrexone has been advocated for a variety of medical problems. Only a few articles published in peer review journals have documented side effects of low dose naltrexone. The purpose of this study was to […]

Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis… (Abstract)

Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis by increasing M1-type macrophages and activating the Bax/Bcl-2/caspase-3/PARP pathway Int Immunopharmacol June 2020 https://pubmed.ncbi.nlm.nih.gov/32171145/?from_single_result=32171145&expanded_search_query=32171145 The incidence of colorectal cancer (CRC) is increasing annually worldwide. However, traditional chemotherapy has obvious side effects. Low-dose naltrexone (LDN) has been reported to delay tumor progression, but the mechanism remains unclear. […]

Low-dose Naltrexone Targets the Opioid Growth Factor… (Abstract)

Low-dose Naltrexone Targets the Opioid Growth Factor-Opioid Growth Factor Receptor Pathway to Inhibit Cell Proliferation: Mechanistic Evidence From a Tissue Exp Biol Med (Maywood) September 2011 https://pubmed.ncbi.nlm.nih.gov/21807817/ Naltrexone (NTX) is an opioid antagonist that inhibits or accelerates cell proliferation in vivo when utilized in a low (LDN) or high (HDN) dose, respectively. The mechanism of […]

Michelle Resendez FNP-C – 15th Jan 2020 (LDN, low dose naltrexone)

Michelle Resendez FNP-C – 15th Jan 2020 (LDN, low dose naltrexone) from LDN Research Trust on Vimeo. Michelle  Resendez is a certified family nurse practitioner. She combines her love for alternative and natural medicine alongside traditional medicine. She has successfully treated patients with a diverse range of health conditions that have not responded well to conventional […]